Searched for
EUGIA PHARMA SPECIALTIES
Pharma Q4 outlook mixed: Hospitals steady, generics face revlimid dragIndian pharma and healthcare firms face a mixed March quarter. While hospitals anticipate steady growth, generic drugmakers grapple with lo...- Aurobindo Pharma's Eugia Unit-3 gets warning letter from USFDA, shares fallAurobindo Pharma's subsidiary Eugia Pharma Specialities received a warning letter from the USFDA concerning its formulations manufacturing ...
- Aurobindo may take its injectable unit publicAurobindo Pharma is revisiting plans to sell a strategic stake in its injectable unit, Eugia Pharma Specialities, focusing on an IPO. Previ...
- Aurobindo puts its injectables business on the block, againAurobindo Pharma promoters have begun the process of selling a majority stake in its injectables business, Eugia Pharma Specialities, after...
- Aurobindo Pharma eyes $5-B revenue in 5 yearsAurobindo Pharma has undergone a significant reorganisation, restructuring its operations into three subsidiaries. Eugia Pharma Specialitie...
- Aurobindo Pharma aims to complete Rs 2000 Cr Pen-G plant in Andhra Pradesh by March'24Out of Rs 2000 crore, the drug maker has already spent around Rs 500 crore and Rs 1,500 crore is going to be spent in the coming year. The ...
- Aurobindo Pharma arm gets final US FDA nod for Vasopressin injectionNew Delhi, Aug 16 (PTI) Aurobindo Pharma Ltd on Tuesday said its wholly-owned arm Eugia Pharma Specialties Ltd has received final approval ...
- Aurobindo calls off Eugia Pharma Specialities sale on valuation mismatchThe Hyderabad-based promoter family of V Ramprasad Reddy and K Nityanand Reddy currently own 51.8% of Aurobindo, a vertically integrated ph...
- Stocks in the news: Tata Steel, Hero Moto, Titan, Britannia, Info Edge and Adani stocksAdani Green, Kotak Mahindra Bank, Adani Total Gas, Havells, Tata Consumer Products, ABB India, Deepak Nitrite, IIFL Wealth, Laxmi Organics,...
- Blackstone closing in on Aurobindo's injectables businessThe keenly contested transaction, now in the final stages of negotiations, pits Blackstone against Baring Private Equity Asia, the only oth...
- Aurobindo Pharma Q3 results: Net profit zooms over four-fold to Rs 2,946 crThe consolidated revenue from operations of the company stood at Rs 6,364.91 crore. It was Rs 5,895 crore for the same period a year ago.
Load More
